Type 1 innate lymphoid cells serve as a diagnostic biomarker for sarcoidosis, and the CXCR4 inhibitor plerixafor, an FDA-approved drug, may provide a targeted treatment. The gene discussed is CXCR4; the disease is sarcoidosis.